CANbridge Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- CANbridge Pharmaceuticals's estimated annual revenue is currently $15.3M per year.
- CANbridge Pharmaceuticals's estimated revenue per employee is $201,000
- CANbridge Pharmaceuticals's total funding is $224.1M.
Employee Data
- CANbridge Pharmaceuticals has 76 Employees.
- CANbridge Pharmaceuticals grew their employee count by 7% last year.
CANbridge Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, chairman and CEO | Reveal Email/Phone |
2 | Chief Commercial Officer (CCO) | Reveal Email/Phone |
3 | Head CMC and Process Development | Reveal Email/Phone |
4 | VP Regulatory Affairs Jobs | Reveal Email/Phone |
5 | Head Information Technology | Reveal Email/Phone |
6 | Director Investor Relations | Reveal Email/Phone |
7 | Chief Financial Officer | Reveal Email/Phone |
8 | Chief Commercial Officer | Reveal Email/Phone |
9 | Senior Director, CMC | Reveal Email/Phone |
10 | VP/Head Global Research | Reveal Email/Phone |
CANbridge Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is CANbridge Pharmaceuticals?
CANbridge Pharmaceuticals Inc. is a China-focused biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region. CANbridge has been recognized as a leader in orphan diseases in China. It has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. In greater China, it has an exclusive licensing agreement to commercialize Hunterase®, an enzyme replacement therapy for the treatment of Hunter syndrome, developed by GC Pharma and marketed in more than ten countries worldwide. CANbridge also has an oncology portfolio, which includes exclusive rights to develop and commercialize Puma Biotechnology's NERLYNX® (neratinib), in greater China, as well as rights to other novel candidates.
keywords:N/A
$224.1M
Total Funding
76
Number of Employees
$15.3M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CANbridge Pharmaceuticals News
CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food...
CANbridge Pharmaceuticals Inc. (CANbridge, stock code 1228.HK) is a China-based global biopharmaceutical company committed to the research,...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.8M | 76 | 0% | N/A |
#2 | $24.7M | 76 | -3% | N/A |
#3 | $11M | 76 | N/A | N/A |
#4 | $13.7M | 76 | 9% | N/A |
#5 | $13.7M | 76 | 23% | N/A |